RxDoctor Payments Data

Rabih Nayfe, MD

Rheumatology · Myrtle Beach, SCNPI 1760823553

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 1,078 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 49 manufacturers reported payments, led by AbbVie at 30.3% of the total.

$21,097in general payments, 2019–2025

Across 1,078 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Amgen$4K
  • Johnson & Johnson$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$640
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$21,042100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,097 in reported general payments places this provider in the 80th percentile of 123 rheumatology providers in South Carolina.

See all rheumatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,179,278
Medicare patients
789
Services billed
268,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib70$499,046
Xeljanz XrTofacitinib Citrate38$316,083
Enbrel SureclickEtanercept21$221,742
Humira(Cf) PenAdalimumab29$197,743
Orencia ClickjectAbatacept24$155,577
Cimzia (2 Pack)Certolizumab Pegol24$145,935
KevzaraSarilumab18$76,609
OtrexupMethotrexate/Pf21$29,439
Hydroxychloroquine Sulfate308$20,625
ProliaDenosumab11$19,427
RasuvoMethotrexate/Pf17$17,630
MethotrexateMethotrexate Sodium401$14,089
Leflunomide133$8,919
Mycophenolate Mofetil39$4,654
Celecoxib60$3,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$6,385$499,04670 claims
UCB, Inc.Cimzia (2 Pack)$1,776$145,93524 claims
Antares Pharma, Inc.Otrexup$278$29,43921 claims
AmgenProlia$3,686$19,42711 claims
Scilex Pharmaceuticals Inc.Colchicine$16$1,05713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 123 rheumatology providers in South Carolina.

Other rheumatology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →